High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma
Authors:
- 31 July 2014
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (2) , 267-272
Abstract
Desumoylating isopeptidase 2 (DESI2) is a recently identified protein with unclear functions. In this study, a total of 132 tissue samples of pancreatic ductal adenocarcinoma and 73 samples of pancreatic normal tissues were explored to assess DESI2 expression and its implications to AKT/mTOR signal. Immunohistochemistry showed DESI2 expression is significantly decreased in cancer tissues versus normal tissues, presenting lowest level in poorly differentiated cancer. Unlike DESI2, the key factors in AKT/mTOR pathway including p-AKT, mTOR, p-mTOR and p-P70S6K present high expression in pancreatic cancer. It is notable that p-mTOR is significantly increased in DESI2-lower cancer compared with DESI2-higher cancer, although mTOR presents no difference in the two groups. The relative p-mTOR/mTOR ratio is also significantly elevated in DESI2-lower cancer. Moreover, the samples whose p-AKT and p-mTOR scores both exceed the median are obviously increased in DESI2-lower cancer compared with DESI2-higher cancer. As a downstream molecule of AKT/mTOR pathway, p-P70S6K was found to display higher level in DESI2-lower pancreatic cancer. High phosphorylation status of those proteins in DESI2-reduced pancreatic cancer indicates that there is high activity of AKT/mTOR signal in condition of DESI2 reduction, which could provide clues to reveal the implications of DESI2 in carcinogenesis.Keywords
This publication has 26 references indexed in Scilit:
- Comprehensive analysis of expression profile reveals the ubiquitous distribution of PPPDE peptidase domain 1, a Golgi apparatus component, and its implications in clinical cancerBiochimie, 2013
- Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathwaysOncology Reports, 2012
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesBMC Cancer, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)Oncology Reports, 2010
- SUMOylation and deSUMOylation at a glanceJournal of Cell Science, 2009
- PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cellsMolecular and Cellular Biochemistry, 2009
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic CancerJournal of Clinical Oncology, 2009
- Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathwayNature Immunology, 2008
- Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequencesProceedings of the National Academy of Sciences, 2002